Advertisement

Embolization pp 115-133 | Cite as

Chemoembolizations and Hepatic Intra-arterial Chemotherapies

  • Pascal Chabrot
  • Agaïcha Alfidja Lankoande
  • Eric Dumousset
  • Armand Abergel
  • Denis Pezet
  • Louis Boyer
Chapter

Abstract

Intra-arterial chemoembolization allows the administration of embolic agents and/or drugs to treat arterialized liver tumors, thus reducing the systemic side effects and sparing the disease-free liver parenchyma. Various techniques can be performed: transarterial embolization (TAE), transarterial chemo-infusion (TACI) with a high concentration of chemotherapy agents and minimal embolization, transarterial chemoembolization (TACE), and chemoembolization with drug-eluting beads (DEB TACE). Irradiation techniques are also therapeutic alternatives such as radioembolization with yttrium 90 and injection of radioactive Lipiodol (I 131): these highly specialized techniques are at the crossroads of interventional radiology, nuclear medicine, and radiotherapy, thus will not be developed in this chapter.

Keywords

Portal Vein Thrombosis Transarterial Embolization Bland Embolization Embolization Session Percutaneous Endovascular Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bruix J, Sherman M. Practice guidelines committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Bruix J, Sherman M. Management of hepato cellular carcinoma: an update AASLD practice guidelines. Hepatology. 2010;53:1–34.CrossRefGoogle Scholar
  3. 3.
    Grieco A, Pompili M, Caminit G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma under-going non-surgical therapy: comparison of Okuda, CLIP, and BCLC straging systems in a single Italian centre. Gut. 2005;54:411–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40(3):225–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepato cellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRefGoogle Scholar
  7. 7.
    Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234–46.PubMedCrossRefGoogle Scholar
  8. 8.
    Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Bouvier A, Ozenne V, Aubé C, et al. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol. 2011;21:1719–26.PubMedCrossRefGoogle Scholar
  10. 10.
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Chua CT, Liauw W, Saxena A. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30:166–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Gerunda GE, Neri D, Merenda R, et al. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl. 2000;6:619–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg. 1995;82:122–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res. 1996;87:206–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Cherqui D, Piedbois P, Pierga JY, et al. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer. 1994;73:2721–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Shimoda M, Bando T, Nagata T, et al. Prophylactic chemolipiodolization for postoperative hepatoma patients. Hepatogastroenterology. 2001;48:493–7.PubMedGoogle Scholar
  17. 17.
    Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801.PubMedCrossRefGoogle Scholar
  18. 18.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–61.CrossRefGoogle Scholar
  20. 20.
    Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.PubMedCrossRefGoogle Scholar
  21. 21.
    Llovet JM, Bruix J. A systematic review of randomized trials for unresectable hepatocellular carcinoma chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:115–20.CrossRefGoogle Scholar
  25. 25.
    Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Chu QD, Hill HC, Douglass HO, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9:855–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Salman HS, Cynamon J, Jagust M, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer. 2002;2:173–9.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765–74.PubMedCrossRefGoogle Scholar
  2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update – AASLD practice guidelines. Hepatology. 2010;53:1–34.CrossRefGoogle Scholar
  3. Cleveland TJ, Kelekis AD, Kopp C, et al. CIRSE take force on clinical pratice: Hepato Cellular Carinoma. In: Clinical practice in interventional radiology CIRSE, Vienna 2007. p. 74–9.Google Scholar
  4. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234–46.PubMedCrossRefGoogle Scholar
  5. Liapi E, Geschwind JF. Transcatheter arterial chemo embolization for liver cancer: is it time to distinguish conventional from drug eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37–49.PubMedCrossRefGoogle Scholar
  6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40(3):225–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Pascal Chabrot
    • 1
  • Agaïcha Alfidja Lankoande
    • 1
  • Eric Dumousset
    • 1
  • Armand Abergel
    • 2
  • Denis Pezet
    • 3
  • Louis Boyer
    • 1
  1. 1.Department of RadiologyUniversity Hospital of Clermont-FerrandClermont-FerrandFrance
  2. 2.Department of HepatogastroenterologyUniversity Hospital of Clermont-FerrandClermont-FerrandFrance
  3. 3.Department of Abdominal SurgeryUniversity Hospital of Clermont-FerrandClermont-FerrandFrance

Personalised recommendations